文献速递骨质疏松与代谢性骨病

选择性5-羟色胺再摄取抑制剂对骨密度的影响:系统综述与荟萃分析

Effect of selective serotonin reuptake inhibitors on bone mineral density: a systematic review and meta-analysis.
PubMed 文献 · Osteoporos Int · 2018-02-12

该系统综述与荟萃分析纳入11项研究,比较SSRI使用者与非使用者骨密度,发现SSRI使用与腰椎骨密度降低显著相关(SMD -0.40;95%CI -0.79至0.00;p=0.05),尤其在老年人中骨丢失更明显;全髋和股骨颈骨密度无显著关联。

要点

  • SSRI使用与腰椎骨密度降低显著相关(SMD -0.40;95%CI -0.79至0.00;p=0.05)。
  • SSRI使用与腰椎骨密度Z评分降低显著相关(SMD -0.28;95%CI -0.50至-0.05;p=0.02)。
  • SSRI使用与全髋及股骨颈骨密度无显著关联。

核心结论

  • SSRI使用是腰椎骨密度降低的危险因素,尤其对老年人。

研究设计与样本

  • 系统综述与荟萃分析,检索PubMed、Scopus、ISI Web of Knowledge、Cochrane Library和PsycINFO截至2017年11月前发表的英文研究,最终纳入11项研究。

主要发现

  • SSRI使用与腰椎骨密度降低显著相关(SMD -0.40;95%CI -0.79至0.00;p=0.05)。
  • SSRI使用与腰椎骨密度Z评分降低显著相关(SMD -0.28;95%CI -0.50至-0.05;p=0.02)。
  • SSRI使用与全髋和股骨颈骨密度无显著关联。
  • SSRI使用与老年人更大的骨丢失相关。

局限性

  • 未来需在不同骨骼部位、男性和女性中开展更大样本量的研究以探讨SSRI使用与骨代谢及骨量的关系。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Our work is the first systematic meta-analysis to investigate the effect of selective serotonin reuptake inhibitor (SSRI) medication on bone mineral density. Through meta-analyzed 11 studies, our findings suggested that compared with nonusers, use of SSRIs was significantly associated with lumbar spine BMD reduction, particularly for old people. The use of selective serotonin reuptake inhibitors (SSRIs) has already been associated with bone mass loss. Their effects on bone mineral density (BMD) for the different bone sections have, however, thus been inconsistent. Here, we aim to assess the effects of SSRIs on BMD using a meta-analysis. We searched PubMed, Scopus, ISI Web of Knowledge, the Cochrane Library, and PsycINFO for all English-written studies investigating the effects of SSRIs on BMD and published before November 2017. BMD was compared between non-SSRI users and SSRI users using a random-effect model with standardized mean differences (SMD) and 95% confidence intervals (CIs). Furthermore, subgroup analyses were performed based on study design, age, and sex in order to find the origins of high heterogeneity. Eleven studies met the inclusion criteria and were used for the meta-analysis. Our study demonstrated that the use of SSRIs was significantly associated with lower BMD values (SMD - 0.40; 95% CI - 0.79 to 0.00; p = 0.05) and BMD Z-scores (SMD - 0.28; 95% CI - 0.50 to - 0.05; p = 0.02) of the lumbar spine, but not of the total hip and femoral neck. In addition, SSRI use was associated with a greater bone loss in older people. SSRI use is a risk factor of lower BMD of the lumbar spine, especially for older people. Future studies into the relationship between SSRI use and bone metabolism and bone mass need to be conducted with larger sample sizes for both men and women at different bone sites.

来源:Osteoporos Int,查看原文。版权归原作者所有。

引用

  1. Zhou C, Fang L, Chen Y, et al. Effect of selective serotonin reuptake inhibitors on bone mineral density: a systematic review and meta-analysis. Osteoporos Int. 2018. PMID: 29435621. doi:10.1007/s00198-018-4413-0

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。